Literature DB >> 27059200

Toll-like receptor 3 pre-conditioning increases the therapeutic efficacy of umbilical cord mesenchymal stromal cells in a dextran sulfate sodium-induced colitis model.

Patricia Fuenzalida1, Mónica Kurte1, Catalina Fernández-O'ryan1, Cristina Ibañez1, Melanie Gauthier-Abeliuk1, Ana María Vega-Letter1, Paz Gonzalez2, Carlos Irarrázabal3, Nataly Quezada1, Fernando Figueroa1, Flavio Carrión4.   

Abstract

BACKGROUND AIMS: Immunomodulatory properties of human umbilical cord-derived mesenchymal stromal cells (UCMSCs) can be differentially modulated by toll-like receptors (TLR) agonists. Here, the therapeutic efficacy of short TLR3 and TLR4 pre-conditioning of UCMSCs was evaluated in a dextran sulfate sodium (DSS)-induced colitis in mice. The novelty of this study is that although modulation of human MSCs activity by TLRs is not a new concept, this is the first time that short TLR pre-conditioning has been carried out in a murine inflammatory model of acute colitis.
METHODS: C57BL/6 mice were exposed to 2.5% dextran sulfate sodium (DSS) in drinking water ad libitum for 7 days. At days 1 and 3, mice were injected intraperitoneally with 1 × 10(6) UCMSCs untreated or TLR3 and TLR4 pre-conditioned UCMSCs. UCMSCs were pre-conditioned with poly(I:C) for TLR3 and LPS for TLR4 for 1 h at 37°C and 5% CO2. We evaluated clinical signs of disease and body weights daily. At the end of the experiment, colon length and histological changes were assessed.
RESULTS: poly(I:C) pre-conditioned UCMSCs significantly ameliorated the clinical and histopathological severity of DSS-induced colitis compared with UCMSCs or LPS pre-conditioned UCMSCs. In contrast, infusion of LPS pre-conditioned UCMSCs significantly increased clinical signs of disease, colon shortening and histological disease index in DSS-induced colitis.
CONCLUSIONS: These results show that short in vitro TLR3 pre-conditioning with poly(I:C) enhances the therapeutic efficacy of UCMSCs, which is a major breakthrough for developing improved treatments to patients with inflammatory bowel disease.
Copyright © 2016 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell therapy; dextran sulfate sodium–induced colitis; immunosuppression; inflammatory bowel disease; toll-like receptors; umbilical cord–derived mesenchymal stromal cells

Mesh:

Substances:

Year:  2016        PMID: 27059200     DOI: 10.1016/j.jcyt.2016.02.002

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  24 in total

1.  Forkhead box O1 (FOXO1) controls the migratory response of Toll-like receptor (TLR3)-stimulated human mesenchymal stromal cells.

Authors:  Sun Hwa Kim; Amitabh Das; Hae In Choi; Ki Hoon Kim; Jin Choul Chai; Mi Ran Choi; Bert Binas; Kyoung Sun Park; Young Seek Lee; Kyoung Hwa Jung; Young Gyu Chai
Journal:  J Biol Chem       Date:  2019-04-03       Impact factor: 5.157

Review 2.  Interferon regulatory factor signaling in autoimmune disease.

Authors:  Bharati Matta; Su Song; Dan Li; Betsy J Barnes
Journal:  Cytokine       Date:  2017-03-07       Impact factor: 3.861

Review 3.  Immunomodulatory plasticity of mesenchymal stem cells: a potential key to successful solid organ transplantation.

Authors:  Urvashi Kaundal; Upma Bagai; Aruna Rakha
Journal:  J Transl Med       Date:  2018-02-15       Impact factor: 5.531

4.  The effect of poly I:C or LPS priming on the therapeutic efficacy of mesenchymal stem cells in an adjuvant-induced arthritis rat model.

Authors:  Samira Zolfaghari; Peiman Brouki Milan; Ahmad Reza Dehpour; Motahareh Rajabi Fomeshi; Fatemeh Eskandari; Loghman Ebrahimi; Seyed Mahmoud Hashemi; Mohammad Taghi Joghataei
Journal:  Pharmacol Rep       Date:  2022-07-17       Impact factor: 3.919

5.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review.

Authors:  Alessander Leyendecker; Carla Cristina Gomes Pinheiro; Mariane Tami Amano; Daniela Franco Bueno
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

Review 6.  Modulation of Immunoregulatory Properties of Mesenchymal Stromal Cells by Toll-Like Receptors: Potential Applications on GVHD.

Authors:  Bruno Sangiorgi; Rodrigo Alexandre Panepucci
Journal:  Stem Cells Int       Date:  2016-09-21       Impact factor: 5.443

7.  Intrinsic Variability Present in Wharton's Jelly Mesenchymal Stem Cells and T Cell Responses May Impact Cell Therapy.

Authors:  Fernanda Vieira Paladino; Luiz Roberto Sardinha; Carla Azevedo Piccinato; Anna Carla Goldberg
Journal:  Stem Cells Int       Date:  2017-07-05       Impact factor: 5.443

Review 8.  Mesenchymal Stromal Cells and Toll-Like Receptor Priming: A Critical Review.

Authors:  Mehdi Najar; Mohammad Krayem; Nathalie Meuleman; Dominique Bron; Laurence Lagneaux
Journal:  Immune Netw       Date:  2017-04-20       Impact factor: 6.303

9.  Differential TLR activation of murine mesenchymal stem cells generates distinct immunomodulatory effects in EAE.

Authors:  Ana María Vega-Letter; Mónica Kurte; Catalina Fernández-O'Ryan; Melanie Gauthier-Abeliuk; Patricia Fuenzalida; Ivón Moya-Uribe; Claudia Altamirano; Fernando Figueroa; Carlos Irarrázabal; Flavio Carrión
Journal:  Stem Cell Res Ther       Date:  2016-10-10       Impact factor: 6.832

Review 10.  Preconditioning of Human Mesenchymal Stem Cells to Enhance Their Regulation of the Immune Response.

Authors:  Arman Saparov; Vyacheslav Ogay; Talgat Nurgozhin; Medet Jumabay; William C W Chen
Journal:  Stem Cells Int       Date:  2016-10-16       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.